Patients with TNBC who receive any chemotherapy (median of responder 369 (n = 1324) vs. non-responder 372 (n = 732) (Figure 5a) and anti-HER2 therapy 156 (n = 443) vs. non-responder 203 (n = 993) (Figure 5b) do not significantly vary from those who do not receive any form of treatment compared to all subtype of BC. Here, ERBB2 is linked to breast cancer.